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In an effort to address the donor shortage issue, living-donorlobar lung transplantation has been performed with satisfac-tory intermediate survival and functional results.1 Because alimited amount of lung tissue is transplanted, this type of
operation seems to be best suited for children2 and small adults and
has been applied almost exclusively in patients with cystic fibrosis.
To our knowledge, this is the first reported case of living-donor
lobar lung transplantation for primary pulmonary hypertension
(PPH) in an adult.
Clinical Summary
A 19-year-old female patient received a diagnosis of PPH in 1996,
at the age of 14 years. Continuous intravenous infusion of
epoprostenol (prostacyclin) was initiated. After an initial improve-
ment to New York Heart Association class II, her condition began
to deteriorate in 1998. Despite high-dose epoprostenol therapy
(140-160 ng · kg–1 · min–1), her status deteriorated to class III in
2000. On November 4, massive hemoptysis developed and she was
urgently admitted with signs of right-sided heart failure. Right heart
catheterization revealed highly elevated pulmonary arterial pressure
(systolic/diastolic/mean: 80/40/58 mm Hg) and severely reduced
cardiac index (1.4 L · min–1 · m–2). High-dose intravenous inotrop-
ic therapy with diuretics was initiated. A second catheter examina-
tion on December 15 revealed minor improvement in cardiac index
with persistent high pulmonary artery pressure (Table 1). Two-
dimensional echocardiography demonstrated a dilated hypokinetic
right ventricle in association with an enlarged right atrium and pul-
monary artery, as well as massive tricuspid regurgitation. Left ven-
tricular function was normal apart from flattening of the interven-
tricular septum. The right ventricular ejection fraction was 14.7%
by first-pass nuclear angiography. She was completely bedridden
and required continuous oxygen inhalation (4 L/min).
On January 5, 2001, she underwent living-donor lobar lung
transplantation with a right lower lobe from her father (51 years
old) and a left lower lobe from her mother (50 years old).
Preoperative chest x-ray films of the recipient and the two donors
showed that the three were quite similar in size (Figure 1). The
height and weight were 157 cm and 38.0 kg for the recipient, 172
cm and 71.0 kg for the father, and 157 cm and 55.0 kg for the
mother.
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Figure 1. Preoperative chest x-ray films of the recipient and the
two donors showed similarity in size. A, Right lower lobe donor;
51-year-old father. B, Recipient; 19-year-old daughter. C, Left lower
lobe donor; 50-year-old mother. 
Figure 2. Chest x-ray film 50 days after living-donor lobar lung
transplantation. Well-expanded grafts filled the chest cavity,
leaving no detectable dead space without cardiomegaly.
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Because of the recipient’s poor preoperative condition, partial
cardiopulmonary bypass was initiated via the femoral vessels
under local anesthesia. Then, the recipient was anesthetized and
intubated. The surgical and logistic aspects of the right and left
donor lobectomy, the donor lobe back-table preservation tech-
nique, and the recipient bilateral pneumonectomy and bilateral
lobar implantation have been previously described by Starnes’s
group.1 In the immediate reperfusion period, she had pulmonary
edema in the left graft and continued pulmonary hypertension. The
right pulmonary arterial anastomosis was found to be severely
kinked. After placement of three tacking stitches, gas exchange
and pulmonary arterial pressure improved immediately.
During the early postoperative period, she was treated with var-
ious cardiovascular medications such as intravenous dopamine,
dobutamine, alprostadil (prostaglandin E1), phosphodiesterase III
inhibitor, and inhaled nitric oxide. Postoperative immunosuppres-
sion was a triple drug therapy consisting of tacrolimus, mycopheno-
late mofetil, and prednisone. The patient was completely weaned
from the respirator within 12 days. The postoperative right heart
catheterization on day 50 revealed remarkable improvement in pul-
monary hemodynamics (Table 1). Right ventricular ejection frac-
tion and arterial blood gases were excellent. Echocardiographic
changes included a decrease in right atrial and ventricular diame-
ter, round left ventricular shape, and no tricuspid regurgitation. The
chest x-ray film demonstrated well-expanded grafts without car-
diomegaly (Figure 2). The recipient’s forced vital capacity (FVC)
became 1550 mL, or 49.7% of her predicted FVC. She was dis-
charged from the hospital 60 days after transplantation.
Discussion
Significant advances in medical treatment of PPH have been
achieved by continuous intravenous epoprostenol therapy in the
past decade.3 Although most patients who have improvement of
their condition with epoprostenol maintain this response, sudden
deterioration or life-threatening complications can occur. This
patient had massive hemoptysis and was thought to have a short
life expectancy without lung transplantation. The only realistic
option for this patient was to receive living-donor lobar lung trans-
plantation, because obtaining brain-dead donors is extremely diffi-
cult in Japan. There were obvious concerns regarding whether pul-
monary hypertension would develop in the two lobes receiving the
patient’s entire cardiac output. Starnes and associates4 have report-
ed successful living-donor lobar lung transplantation in 4 patients
with PPH; however, all of them were younger than 15 years. This
patient was an adult: therefore, preoperative chest x-ray films indi-
cated that the recipient and the two donors were quite similar in
size. The father’s FVC was 4360 mL and the mother’s 2970 mL.
Given that the right lower lobe consists of 5 segments and the left
lower lobe of 4, total FVC of the 2 grafts was estimated to be 1773
mL ([4360 mL × 5]/19 + [2970 mL × 4]/19), or 56.8% of the recip-
ient’s predicted FVC (3118 mL). We thought that 56.8% was with-
in an acceptable range since single lung transplantation had been
performed successfully for patients with PPH.5 Pulmonary arterial
pressure became nearly normal within 2 months, validating the
functional capacity of the two adult lobes to handle the cardiac out-
put of the adult recipient with PPH.
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TABLE I. Assessment of lung and cardiac function
Before After transplantation
transplantation (2 mo)
PAP (mm Hg) 84/48 (58) 33/12 (19)
PCWP (mm Hg) 11 8
CVP (mm Hg) 8 0
CI (L · min–1 · m–2) 1.8 3.2
RVEF (%) 14.7 76.6
PaO2 (mm Hg) 82.2 (O2 4 L/min) 96.0 (room air)
PaCO2 (mm Hg) 25.2 39.6
PAP, Pulmonary artery pressure; PCWP, pulmonary capillary wedge pres-
sure; CVP, central venous pressure; CI, cardiac index; RVEF, right ventric-
ular ejection fraction obtained by radionuclide scan; PaO2, arterial oxygen
tension; PaCO2, arterial carbon dioxide tension.
